Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Up 37.2% in April

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Rating) saw a large growth in short interest in April. As of April 30th, there was short interest totalling 4,060,000 shares, a growth of 37.2% from the April 15th total of 2,960,000 shares. Currently, 13.1% of the shares of the company are short sold. Based on an average trading […]

Related Keywords

Canada ,Stella Xu ,Arsani William ,Morgan Stanley ,Design Therapeutics Inc ,Securities Exchange Commission ,Life Insurance Co ,Zacks Investment Research ,Piper Sandler ,Nasdaq ,Sg Americas Securities ,Goldman Sachs Group ,Group Plc ,Royal Bank ,Design Therapeutics ,Get Rating ,Exchange Commission ,Director Arsani William ,General Group Plc ,Investment Research ,Friedreich Ataxia ,Myotonic Dystrophy ,Nasdaq Dsgn ,Dsgn ,Medical ,Stocks ,Options ,Put ,Call ,